In the in vivo setting, the SECH treatments led to the clearance of HIV infection only in a portion of human CD34+ stem cell-reconstituted (Hu-HSC) mice after 35–40 cycles of treatments (17). This evidence concerns the gene CD34 and HIV infectious disease.